Alere Inc. Declares Cash Dividend On Its Series B Convertible Perpetual Preferred Stock
WALTHAM, Mass., March 1, 2013 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). The dividend is payable on April 15, 2013 to holders of record of Series B stock at the close of business on April 1, 2013.
Such payment will cover the amount of all dividends accrued from January 1, 2013 through March 31, 2013.
By developing new capabilities in near-patient diagnosis, monitoring and health information solutions, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology and diabetes. Alere is headquartered in Waltham, Massachusetts.
For more information about Alere, please visit our website at http://www.alere.com.
SOURCE Alere Inc.
RELATED LINKS
http://www.alere.com
More by this Source
Alere to Develop Simple, Affordable Point-of-Care Nucleic Acid Test for Tuberculosis & Expand Manufacturing for POC HIV Viral Load Platform
Mar 01, 2013, 07:00 ET
Alere to Attend Goldman Sachs Leveraged Finance Healthcare Conference on March 6th
Feb 22, 2013, 17:18 ET
Alere to Attend Raymond James 34th Annual Institutional Investors Conference on March 5th
Feb 22, 2013, 17:14 ET
Featured Video
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.





